Meeting News Coverage

HIV did not affect HCC recurrence or survival after LT

Survival and recurrence rates were unaffected by HIV infection among patients who underwent liver transplantation for hepatocellular carcinoma, according to a poster presentation at CROI 2015.

In this prospective cohort study, 74 patients with HIV and HCC who underwent liver transplantation across 22 clinical centers in Spain were matched in a 1:3 ratio with 222 non–HIV-infected patients with HCC who underwent liver transplantation to determine whether HIV infection affected survival or recurrence rates for HCC after liver transplantation. Of all the patients, 86% were men and 92% had hepatitis C virus infection. At the time of liver transplantation, 96% of patients with HIV were undergoing antiretroviral therapy. Median follow-up was 46 months.

Overall, 16% of patients with HIV (n = 12) and 14% of HIV-negative patients (n = 32) developed HCC recurrence. The HCC recurrence rates for both groups were similar at 1, 3 and 5 years. Recurrence rates for HIV-infected patients at 1 year was 7%, 17% at 3 years and 20% at 5 years. In HIV-negative patients, the rate of HCC recurrence at 1 year was 5%, 11% at 3 years and 19% at 5 years.

The survival rate for HIV-infected patients was 87% at 1 year, 78% at 3 years and 69% at 5 years posttransplant. In HIV-negative patients, the survival rate at 1 year was 89%, 78% at 3 years and 73% at 5 years. Microscopic vascular invasion was the only variable independently associated with HCC recurrence (HR = 3.79; 95% CI, 1.67-8.57), whereas HCV and satellite nodules were independently associated with mortality posttransplant.  

“HIV infection did not have any impact on recurrence of HCC or survival after [liver transplantation],” the researchers concluded. “These results support the indication of [liver transplantation] in HIV-infected patients with HCC.” – by Melinda Stevens

Reference:

Agüero FH, et al. Abstract 640.  Presented at: Conference on Retroviruses and Opportunistic Infections; Feb. 23-26, 2015; Seattle.

Disclosure: Relevant financial disclosures were not provided by researchers.

Survival and recurrence rates were unaffected by HIV infection among patients who underwent liver transplantation for hepatocellular carcinoma, according to a poster presentation at CROI 2015.

In this prospective cohort study, 74 patients with HIV and HCC who underwent liver transplantation across 22 clinical centers in Spain were matched in a 1:3 ratio with 222 non–HIV-infected patients with HCC who underwent liver transplantation to determine whether HIV infection affected survival or recurrence rates for HCC after liver transplantation. Of all the patients, 86% were men and 92% had hepatitis C virus infection. At the time of liver transplantation, 96% of patients with HIV were undergoing antiretroviral therapy. Median follow-up was 46 months.

Overall, 16% of patients with HIV (n = 12) and 14% of HIV-negative patients (n = 32) developed HCC recurrence. The HCC recurrence rates for both groups were similar at 1, 3 and 5 years. Recurrence rates for HIV-infected patients at 1 year was 7%, 17% at 3 years and 20% at 5 years. In HIV-negative patients, the rate of HCC recurrence at 1 year was 5%, 11% at 3 years and 19% at 5 years.

The survival rate for HIV-infected patients was 87% at 1 year, 78% at 3 years and 69% at 5 years posttransplant. In HIV-negative patients, the survival rate at 1 year was 89%, 78% at 3 years and 73% at 5 years. Microscopic vascular invasion was the only variable independently associated with HCC recurrence (HR = 3.79; 95% CI, 1.67-8.57), whereas HCV and satellite nodules were independently associated with mortality posttransplant.  

“HIV infection did not have any impact on recurrence of HCC or survival after [liver transplantation],” the researchers concluded. “These results support the indication of [liver transplantation] in HIV-infected patients with HCC.” – by Melinda Stevens

Reference:

Agüero FH, et al. Abstract 640.  Presented at: Conference on Retroviruses and Opportunistic Infections; Feb. 23-26, 2015; Seattle.

Disclosure: Relevant financial disclosures were not provided by researchers.

    See more from Conference on Retroviruses and Opportunistic Infections (CROI)